MacroGenics(MGNX)

Search documents
MacroGenics (MGNX) Investor Presentation - Slideshow
2021-03-01 19:23
® Corporate Presentation February 25, 2021 The information in this slide deck is current as of February 25, 2021, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, plans and prospects for MacroGenics ("Company"), incl ...
MacroGenics(MGNX) - 2020 Q4 - Earnings Call Transcript
2021-02-26 03:59
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2020 Earnings Conference Call February 25, 2020 4:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and Chief Executive Officer Jim Karrels - Senior Vice President and Chief Financial Officer Conference Call Participants Evan Seigerman - Credit Suisse David Ruch - SVB Leerink Bo Chen - Evercore ISI David Lebowitz - Morgan Stanley Mitchell Kapoor - Barclays Operator Good afternoon. We will begin the MacroGenics 2020 Fourth Quarter a ...
MacroGenics(MGNX) - 2020 Q4 - Annual Report
2021-02-25 21:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, INC. (Exact name of registrant) Delaware 06-1591613 (State of organization) (I.R.S. Employer Identification Number ...
MacroGenics (MGNX) Investor Presentation - Slideshow
2020-12-04 19:23
® Corporate Presentation December 1, 2020 The information in this slide deck is current as of December 1, 2020, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, plans and prospects for MacroGenics ("Company"), includ ...
MacroGenics(MGNX) - 2020 Q3 - Earnings Call Presentation
2020-11-09 16:12
® Developing Breakthrough Biologics, Life-changing Medicines™ Corporate Presentation November 4, 2020 The information in this slide deck is current as of November 4, 2020, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectati ...
MacroGenics(MGNX) - 2020 Q3 - Earnings Call Transcript
2020-11-06 05:05
MacroGenics, Inc. (NASDAQ:MGNX) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and CEO Jim Karrels - CFO Stephen Eck - CMO Conference Call Participants Yigal Nochomovitz - Citigroup Evan Seigerman - Credit Suisse Jonathan Miller - Evercore Stephen Willey - Stifel Etzer Darout - Guggenheim Securities Peter Lawson - Barclays Yigal Nochomovitz - Citigroup Operator Good afternoon. We will begin the MacroGenics 2020 ...
MacroGenics(MGNX) - 2020 Q3 - Quarterly Report
2020-11-04 21:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) | Title of each class | Trading Symbol(s) | Name of eac ...
MacroGenics (MGNX) Investor Presentation - Slideshow
2020-09-17 18:38
| --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | ® | | | | | | | Developing Breakthrough Biologics, Life-changing Medicines™ | | | | | | | | | | | | | | Corporate Presentation September 14, 2020 | | | | | | The information in this slide deck is current as of September 14, 2020, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Cu ...
MacroGenics(MGNX) - 2020 Q2 - Earnings Call Transcript
2020-08-01 01:35
MacroGenics, Inc. (NASDAQ:MGNX) Q2 2020 Earnings Conference Call July 30, 2020 4:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and CEO Jim Karrels - CFO Stephen Eck - CMO Conference Call Participants Debjit Chattopadhyay - H.C. Wainwright Paul Jeng - Guggenheim Securities Jonathan Miller - Evercore ISI Jonathan Chang - SVB Leerink Stephen Willey - Stifel Samantha Semenkow - Citi Peter Lawson - Barclays David Lebowitz - Morgan Stanley David Nierengarten - Wedbush ...
MacroGenics(MGNX) - 2020 Q2 - Quarterly Report
2020-07-31 01:58
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpor ...